Prostate cancer, particularly its castration-resistant form, represents a formidable clinical challenge due to its ability to evade androgen deprivation therapies and conventional chemotherapy. Docetaxel remains a cornerstone treatment for advanced stages, yet resistance invariably develops, compromising patient outcomes. The newly reported findings spotlight the crucial involvement of histone lactylation in orchestrating cellular pathways that promote this resistance, thereby offering key insights into the molecular sabotaging of chemotherapeutic efficacy.

Histone proteins, fundamental components of chromatin, undergo diverse chemical modifications that influence DNA accessibility and transcriptional activity. Lactylation, the addition of a lactyl group to lysine residues on histones, has emerged as a unique regulator linking cellular metabolism to epigenetic control. This study demonstrates that elevated lactylation levels are prevalent in CRPC cells exhibiting docetaxel resistance, suggesting a direct connection between metabolic shifts and epigenetic reprogramming in cancer progression.

Delving into the mechanistic landscape, researchers identified that the modulation of the actin-binding protein Calponin 1 (CNN1) acts as a central mediator in this pathway. CNN1, traditionally associated with cytoskeletal dynamics, has been co-opted in resistant prostate cancer cells to activate autophagy—a self-digestive process that enables tumor cells to survive under therapeutic stress. This autophagic induction not only facilitates cell survival but also enforces cell cycle arrest, enabling cancer cells to enter a quiescent-like state refractory to chemotherapy.

The intricate link between histone lactylation and CNN1-driven autophagy paints a complex picture whereby metabolic rewiring influences chromatin state, which in turn governs cytoskeletal and survival pathways. This cascade ultimately supports tumor cell endurance against docetaxel, highlighting a multifaceted resistance mechanism that transcends classical genetic mutations and driver oncogene paradigms.

Moreover, the study utilized state-of-the-art biochemical assays and chromatin immunoprecipitation sequencing to establish a comprehensive mapping of lactylated histone sites correlating with upregulated CNN1 expression. These epigenetic marks were found to be enriched near genes implicated in autophagy regulation and cell cycle checkpoints, offering a direct transcriptional basis for the observed phenotypes in resistant tumor cells.

Importantly, pharmacologic inhibition of histone lactylation or genetic silencing of CNN1 significantly sensitized CRPC cells to docetaxel, effectively reversing resistance phenotypes in vitro and in murine xenograft models. This therapeutic vulnerability underscores the translational potential of targeting this chromatin-metabolic axis to enhance chemotherapy outcomes in advanced prostate cancer.

The findings also shed light on the dynamic interplay between tumor metabolism and epigenetic modulation. Increased intracellular lactate levels, often a hallmark of the cancer-associated Warburg effect, serve as substrates for histone lactylation, effectively linking metabolic byproducts to gene expression changes that support tumor survival. This metabolic-epigenetic nexus represents a paradigm shift in understanding how cancer cells leverage altered metabolism to epigenetically sculpt resistance phenotypes.

Intriguingly, the autophagy induced downstream of CNN1 activity does not merely act as a cytoprotective mechanism; it also contributes to the cell cycle arrest state, allowing cancer cells to evade docetaxel’s cytotoxic effects, which predominantly target proliferative cells. This dual role enhances tumor resilience, effectively creating a sanctuary where tumor cells persist unharmed during chemotherapy, ready to reinitiate growth post-treatment.

The study further explores how blockade of autophagy flux in CNN1-overexpressing cells disrupts this protective niche, reinstating the sensitivity of prostate cancer cells to chemotherapy. This suggests that combinatorial treatment regimens targeting histone lactylation, CNN1 function, and autophagic pathways could synergize to circumvent therapy resistance.

Beyond its immediate clinical relevance, this research advances the broader understanding of epigenetic modifiers as dynamic effectors in cancer progression. Histone lactylation emerges as a versatile post-translational mark integrating metabolic cues with chromatin architecture, adding complexity to the epigenetic code influencing tumor biology.

The implications extend to biomarker development, as levels of histone lactylation or CNN1 expression could serve as predictive indicators of docetaxel resistance. Such biomarkers would facilitate personalized treatment strategies, enabling early identification of resistant tumors and the prompt initiation of alternative or adjunctive therapies.

From a therapeutic development standpoint, the enzymes responsible for adding and removing lactyl groups on histones represent promising drug targets. Manipulating these epigenetic ‘writers’ and ‘erasers’ offers an innovative strategy to modulate chromatin states, reverse resistance mechanisms, and sensitize tumors to existing chemotherapies.

This groundbreaking work also encourages reevaluation of metabolic interventions in oncologic treatment, emphasizing the intricate connections between metabolite availability, epigenetic regulation, and cellular survival. Targeting metabolic pathways that fuel aberrant lactylation might disrupt the resistance circuitry at its origin.

Collectively, this study provides compelling evidence that epigenetic modifications like histone lactylation are not mere passive markers but active players in cancer drug resistance and progression. By uncovering the CNN1-mediated autophagy and cell cycle arrest axis, the research opens new horizons in tackling the clinical conundrum of chemotherapy failure in CRPC.

Future investigations are poised to decipher the full spectrum of histone lactylation targets across diverse malignancies, expanding the therapeutic relevance of these findings beyond prostate cancer. Additionally, exploring the crosstalk between lactylation and other histone modifications could unveil cooperative networks governing tumor cell fate decisions under therapeutic pressures.

In summary, the revelation that histone lactylation modification orchestrates docetaxel resistance and tumor progression via a CNN1-autophagy-cell cycle axis marks a transformative milestone in cancer epigenetics. This knowledge lays a robust foundation for the development of novel epigenetic-metabolic therapies designed to outwit tumor resilience mechanisms and improve survival for patients grappling with castration-resistant prostate cancer.

Subject of Research: Histone lactylation modification’s role in docetaxel resistance and tumor progression in castration-resistant prostate cancer.

Article Title: Histone lactylation modification promotes docetaxel resistance and tumor progression through CNN1-Mediated autophagy and cell cycle arrest in Castration-resistant prostate cancer.

Article References: Mao, R., Chen, X., Fu, X. et al. Histone lactylation modification promotes docetaxel resistance and tumor progression through CNN1-Mediated autophagy and cell cycle arrest in Castration-resistant prostate cancer. Cell Death Discov. (2026). https://doi.org/10.1038/s41420-026-03141-8

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41420-026-03141-8

Histone modifications have long captivated cancer researchers due to their profound influence on gene expression and cellular identity. Among these, acetylation and methylation have been extensively studied, laying the foundation for epigenetic therapies. However, histone lactylation, a relatively novel type of modification first described just a few years ago, introduces a metabolic dimension to epigenetic regulation by linking cellular metabolic states directly to gene expression outcomes. This revolutionary idea merges metabolic pathways with chromatin biology, offering fresh perspectives on how cancer cells adapt and thrive.

At its core, histone lactylation involves the addition of lactyl groups derived from lactate onto specific lysine residues of histone proteins. Lactate, a metabolic byproduct traditionally viewed as a waste molecule from anaerobic glycolysis, has gained recognition as an important signaling metabolite. In cancer cells, which frequently exhibit the Warburg effect—a preference for glycolysis even under oxygen-rich conditions—high levels of lactate accumulate within the tumor microenvironment. This surplus of lactate now emerges not just as a metabolic quirk but as a direct epigenetic modulator influencing gene expression via histone lactylation.

The implications of histone lactylation in immune evasion are particularly compelling. Tumor cells often create an immunosuppressive milieu that inhibits the activity of cytotoxic immune cells such as T lymphocytes and natural killer cells. Emerging evidence suggests that histone lactylation may facilitate this immune escape by modulating the transcription of key genes involved in immune checkpoints and cytokine production. This adaptive epigenetic mechanism thereby equips cancer cells with an enhanced ability to ‘hide’ from immune surveillance, posing a significant barrier to immune-based therapies.

Moreover, the role of histone lactylation in promoting therapy resistance is drawing intense attention. Resistance to chemotherapy and targeted therapies remains a leading cause of cancer treatment failure. Studies indicate that cancer cells with elevated histone lactylation levels exhibit a transcriptional profile skewed towards survival pathways and DNA repair mechanisms, making them resilient to traditional cytotoxic agents. This modification appears to act as a metabolic sensor that shifts gene expression to favor resistance phenotypes, underscoring the connection between metabolism, epigenetics, and therapeutic outcomes.

One particularly intriguing dimension of histone lactylation is its reversibility and dynamic regulation. Unlike irreversible genetic mutations, histone modifications are inherently plastic, enabling rapid adaptation of cancer cells to fluctuating environmental stresses. Understanding the enzymatic machinery responsible for writing, reading, and erasing the lactylation mark is an area of active research. Identifying specific lactyltransferases and delactylases could provide molecular targets for next-generation inhibitors designed to disrupt these adaptive epigenetic circuits.

The therapeutic potential of targeting histone lactylation extends beyond direct modulation of tumor cells. Since this modification regulates the expression of genes involved in immune evasion, it offers a promising strategy to enhance the efficacy of immunotherapies. Combining histone lactylation inhibitors with immune checkpoint blockade or adoptive cell therapies could synergistically restore immune competence against resistant tumors, raising hopes for more durable clinical responses.

Importantly, recent preclinical studies have begun to map the landscape of histone lactylation across different cancer types, revealing variable patterns that correlate with metabolic phenotypes and treatment responses. Tumors exhibiting high glycolytic flux and elevated lactate production tend to show robust lactylation signatures, highlighting histone lactylation as a metabolic-epigenetic biomarker. Such insights pave the way for personalized medicine approaches where patients’ tumors are profiled for lactylation status to tailor optimal therapeutic regimens.

Beyond oncology, histone lactylation is gaining recognition in various physiological and pathological contexts including inflammation, infection, and fibrosis. This modification’s involvement in immune cell differentiation and function points to a broader biological relevance. Thus, investigating the crosstalk between histone lactylation and other epigenetic marks continues to unravel complex regulatory networks that govern cell fate decisions in health and disease.

Technological advances such as high-resolution mass spectrometry, chromatin immunoprecipitation sequencing (ChIP-seq), and single-cell epigenomics have been instrumental in characterizing histone lactylation landscapes. These tools enable detailed mapping of lactylation sites and identification of gene targets affected by this modification, providing an essential framework for deciphering its functional consequences. Integration of metabolomics with epigenetic data further enriches understanding of how cellular metabolism and chromatin state co-evolve in cancer progression.

The intricate interplay between metabolism and epigenetics exemplified by histone lactylation underscores the need for interdisciplinary research bridging biochemistry, immunology, and clinical oncology. It challenges the traditional compartmentalization of scientific disciplines and calls for comprehensive approaches to tackle cancer’s adaptability. Future clinical trials evaluating agents that modulate histone lactylation pathways will be critical in translating this fundamental knowledge into tangible therapeutic benefits.

Despite the excitement, several critical questions remain unanswered. The full spectrum of enzymes regulating histone lactylation, the specificity of lactylation at different histone sites, and the downstream transcriptional networks modulated by these marks are subjects of ongoing investigation. Additionally, the potential off-target effects and safety profiles of lactylation-targeting drugs must be thoroughly evaluated before clinical application.

In conclusion, the discovery of histone lactylation as a nexus between cancer metabolism, epigenetic regulation, and immune evasion represents a paradigm shift in understanding tumor biology. By illuminating novel mechanisms driving therapy resistance, it heralds the emergence of innovative therapeutic strategies aiming to disrupt these adaptive processes. As research accelerates, targeting histone lactylation might soon become an integral component of precision oncology, offering renewed hope to patients facing refractory cancers.

Subject of Research: Histone lactylation as a novel epigenetic modification influencing cancer immune evasion and therapy resistance.

Article Title: Histone lactylation: a new target for overcoming immune evasion and therapy resistance.

Article References:
Ghadyani, F., Zandi, P. & Ghafouri-Fard, S. Histone lactylation: a new target for overcoming immune evasion and therapy resistance. Med Oncol 42, 399 (2025). https://doi.org/10.1007/s12032-025-02940-w

Image Credits: AI Generated